Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Typical RS

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Dec 03, 2020 1:06pm

197 Views

Post# 32029285

Typical RS

drifting lower just like 90% of all RS do, you can not use the excuse of low volume i am in a few stocks that are melting up on low volume with no news. current price $3.87. i am thinking $3.05 could be a support level, the 52 week low was 30.5 pre split.
glta

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program